11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

BACKGROUND: Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast cancer, but long-term follow-up data are needed. We report the results of compa...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Lancet
Κύριοι συγγραφείς: Cameron, David, Piccart-Gebhart, Martine J, Gelber, Richard D, Procter, Marion, Goldhirsch, Aron, de Azambuja, Evandro, Castro, Gilberto, Untch, Michael, Smith, Ian, Gianni, Luca, Baselga, Jose, Al-Sakaff, Nedal, Lauer, Sabine, McFadden, Eleanor, Leyland-Jones, Brian, Bell, Richard, Dowsett, Mitch, Jackisch, Christian
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2017
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5465633/
https://ncbi.nlm.nih.gov/pubmed/28215665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(16)32616-2
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια